title: Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions.
authors.affiliation: Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. Paul_Richardson@dfci.harvard.edu
authors.forename: P G
authors.initials: PG
authors.lastname: Richardson
authors.forename: V T
authors.initials: VT
authors.lastname: Ho
authors.forename: C
authors.initials: C
authors.lastname: Cutler
authors.forename: B
authors.initials: B
authors.lastname: Glotzbecker
authors.forename: J H
authors.initials: JH
authors.lastname: Antin
authors.forename: R
authors.initials: R
authors.lastname: Soiffer
mesh_terms: D000293:Adolescent; D000328:Adult; D000617:Aminoglycosides / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D000079982:Gemtuzumab; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000079982:Gemtuzumab; D020123:Sirolimus